The global Blood Cancer Molecular Diagnostics market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of % from 2025 to 2031.

United States market for Blood Cancer Molecular Diagnostics is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Blood Cancer Molecular Diagnostics is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Blood Cancer Molecular Diagnostics is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

This Insight Report provides a comprehensive analysis of the global Blood Cancer Molecular Diagnostics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity.

Segmentation by Type

• Polymerase Chain Reaction
• Molecular Hybridization
• Biochip
• Others

Segmentation by Application

• Hospital
• Third-Party Testing Agency
• Others

Market by Region

• Americas
• APAC
• Europe
• Middle East & Africa

Companies Coverage

• Roche Diagnostics
• Abbott
• Thermo Fisher
• Qiagen
• Illumina
• Agilent
• Liferiver
• Gpmedical
• Zeesan
• Berry Oncology
• Annoroad